What question did this study set out to answer?

To review the evolving landscape of combination pharmacotherapies and novel molecular targets aimed at reducing residual kidney failure and cardiovascular risk in diabetic kidney disease.

August 16, 2026Kidney Research and Clinical PracticeOpen Access

Beyond current standards: combination therapy and emerging targets in diabetic kidney disease

View Full Paper

Ask AI

Bookmark

Authors

JLJiwon LeeCentre for Addiction and Mental Health MYMi‐Yeon YuHanyang University Guri Hospital OGon behalf of the Korean Diabetic Kidney Disease Study Group

Discussion

Member takes

Implication

Review highlights multi-target combination therapies in diabetic kidney disease, suggesting that early multi-pathway intervention mitigates residual cardiorenal risk.

Key Points

To review the evolving landscape of combination pharmacotherapies and novel molecular targets aimed at reducing residual kidney failure and cardiovascular risk in diabetic kidney disease.
Synthesized current clinical evidence on standard renin-angiotensin system blockade alongside established and emerging therapeutic classes for diabetic kidney disease.
Evaluated the complementary biological mechanisms of sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, aldosterone synthase inhibitors, and endothelin receptor antagonists.
Combining sodium-glucose cotransporter 2 inhibitors with nonsteroidal mineralocorticoid receptor antagonists like finerenone provides documented cardiorenal protection beyond single-agent renin-angiotensin system blockade.
Emerging therapies, such as aldosterone synthase inhibitors and endothelin receptor antagonists, show potential in reducing persistent albuminuria and progressive renal fibrosis.
Evidence suggests that early initiation of multi-pathway combination therapy provides clinical advantages, although robust long-term trial data evaluating triple or multidrug regimens remain limited.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a817980f2fb91fc834aca87 https://doi.org/10.23876/j.krcp.26.234

View Full Paper

Ask AI

Bookmark

Implication

Review highlights multi-target combination therapies in diabetic kidney disease, suggesting that early multi-pathway intervention mitigates residual cardiorenal risk.

Beyond current standards: combination therapy and emerging targets in diabetic kidney disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Beyond current standards: combination therapy and emerging targets in diabetic kidney disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider